102 related articles for article (PubMed ID: 26170993)
1. Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Panagopoulos I; Gorunova L; Taksdal I; Bjerkehagen B; Heim S
Oncol Lett; 2015 Jul; 10(1):163-167. PubMed ID: 26170993
[TBL] [Abstract][Full Text] [Related]
2. A novel truncated form of
Agostini A; Panagopoulos I; Davidson B; Trope CG; Heim S; Micci F
Oncol Lett; 2016 Aug; 12(2):1559-1563. PubMed ID: 27446471
[TBL] [Abstract][Full Text] [Related]
3. HMGA2 expression pattern and TERT mutations in tumors of the vulva.
Agostini A; Panagopoulos I; Andersen HK; Johannesen LE; Davidson B; Tropé CG; Heim S; Micci F
Oncol Rep; 2015 Jun; 33(6):2675-80. PubMed ID: 25823555
[TBL] [Abstract][Full Text] [Related]
4. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
5. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas.
Dahlén A; Mertens F; Rydholm A; Brosjö O; Wejde J; Mandahl N; Panagopoulos I
Mod Pathol; 2003 Nov; 16(11):1132-40. PubMed ID: 14614053
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
7.
Arantes LMRB; Cruvinel-Carloni A; de Carvalho AC; Sorroche BP; Carvalho AL; Scapulatempo-Neto C; Reis RM
Front Oncol; 2020; 10():1275. PubMed ID: 32850388
[No Abstract] [Full Text] [Related]
8. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
9. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
10. Convexity dural chondroma: a case report with pathological and molecular analysis.
Sugiura Y; Nagaishi M; Takano I; Tanaka Y; Suzuki K; Yokoo H; Hyodo A
Clin Neuropathol; 2015; 34(1):13-8. PubMed ID: 25250651
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
[TBL] [Abstract][Full Text] [Related]
14. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
15. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
[TBL] [Abstract][Full Text] [Related]
18. Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma.
Jeon MJ; Kim WG; Sim S; Lim S; Kwon H; Kim TY; Shong YK; Kim WB
Endocrinol Metab (Seoul); 2016 Mar; 31(1):100-4. PubMed ID: 26676331
[TBL] [Abstract][Full Text] [Related]
19. HMGA2 and MDM2 expression in lipomatous tumors with partial, low-level amplification of sequences from the long arm of chromosome 12.
Mandahl N; Bartuma H; Magnusson L; Isaksson M; Macchia G; Mertens F
Cancer Genet; 2011 Oct; 204(10):550-6. PubMed ID: 22137485
[TBL] [Abstract][Full Text] [Related]
20. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
